Intellia Therapeutics, INC. (NTLA) SEC Filings — 2024
19 SEC filings for Intellia Therapeutics, INC. (NTLA) in 2024.
Filings
- Intellia Therapeutics Files 8-K — 8-K · Nov 18, 2024
- Intellia Therapeutics Files 8-K for Financials — 8-K · Nov 7, 2024
- Intellia Therapeutics Partners with Regeneron for Autoimmune Disease Therapy — 8-K · Oct 25, 2024
- Intellia Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 8, 2024
- Intellia Therapeutics Announces Executive Appointments — 8-K · Jun 26, 2024
- Intellia Therapeutics Appoints New Officers, Adjusts Compensation — 8-K · Jun 14, 2024
- Intellia Therapeutics Files 8-K — 8-K · Jun 13, 2024
- Intellia Therapeutics Reports First Quarter 2024 Financial Results — 10-Q · May 9, 2024
- Intellia Therapeutics Announces 2024 Annual Meeting of Stockholders on June 12 — DEF 14A · Apr 29, 2024
- Intellia Therapeutics Announces Executive and Board Changes — 8-K · Apr 15, 2024
- Intellia Therapeutics Terminates Deal with Regeneron — 8-K · Mar 22, 2024
- Intellia Therapeutics Enters Material Definitive Agreement — 8-K · Feb 23, 2024
- Intellia Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 22, 2024
- Intellia Therapeutics, INC. SC 13G/A Filing — SC 13G/A · Feb 13, 2024
- Intellia Therapeutics Files Routine 8-K on Jan 31 Event — 8-K · Feb 1, 2024
- ARK Investment Management Holds 12.9% Stake in Intellia Therapeutics — SC 13G/A · Jan 29, 2024
- State Street Corp. Updates Passive Stake in Intellia Therapeutics — SC 13G/A · Jan 24, 2024
- BlackRock Amends Intellia Therapeutics Stake, Signals Confidence — SC 13G/A · Jan 8, 2024
- Intellia Therapeutics Files 8-K on Financial Condition, Other Events — 8-K · Jan 4, 2024